CA2698752A1 — Oral cannabinoid liquid formulations and methods of treatment
Assigned to Insys Therapeutics Inc · Expires 2009-02-12 · 17y expired
What this patent protects
A room temperature stable aqueous cannabinoid formulation is disclosed. In preferred embodiments, the cannabi-noid formulation comprises dronabinol in a mixture of buffer solution, and organic cosolvents such as ethanol, propylene glycol and polyethylene glycol.
USPTO Abstract
A room temperature stable aqueous cannabinoid formulation is disclosed. In preferred embodiments, the cannabi-noid formulation comprises dronabinol in a mixture of buffer solution, and organic cosolvents such as ethanol, propylene glycol and polyethylene glycol.
Drugs covered by this patent
- Temovate (CLOBETASOL PROPIONATE) · Fougera Pharms
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.